Health and Human Services Drug Pricing Forum

Conclusion Overall, the administration seems to believe that the current system, where drugs are priced depending on who is paying for them, winds up "obscuring" the true cost of the drug. Therefore, we can expect to hear many more calls for increased transparency of information available about drug pricing and value. While the issue of drug pricing is quite the newsmaker, the industry continues to emphasize that drug spending makes up just ten percent of health spending overall and the continued growth is expected to rise in line with other health spending. By continuing to point out the same "bad actors" without looking at the bigger picture of what is causing health insurance costs to rise, opportunities are being missed.       Related StoriesSanofi Corporate Integrity Agreement 2015Senators McCain and Grassley Request HHS for Approval of Importation of Certain DrugsSenate Finance Committee Releases Results of Investigation Into Gilead’s Pricing Strategy for Hepatitis-C Drugs 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs